SEC Form 4 · accession 0001144204-18-052403
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Pruzanski
Officer — President & CEO · Director
Period of report
Jan 1, 2018
Accepted (ET)
Oct 3, 2018 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 1, 2018 | F | 3,609 | $58.42 | D | 566,805 | D | |
| Common StockF1,F2 | Apr 1, 2018 | F | 2,050 | $61.52 | D | 566,805 | D | |
| Common StockF1,F2 | Jul 1, 2018 | F | 2,051 | $83.91 | D | 566,805 | D | |
| Common StockF1,F2 | Oct 1, 2018 | F | 2,049 | $126.46 | D | 566,805 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock.
- F2In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4.